Free Trial

Pharming Group (NASDAQ:PHAR) Sets New 12-Month High - Time to Buy?

Pharming Group logo with Medical background

Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $11.72 and last traded at $11.07, with a volume of 4600 shares traded. The stock had previously closed at $10.60.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on PHAR shares. Oppenheimer upped their price objective on shares of Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research note on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a report on Thursday, March 20th.

Read Our Latest Report on Pharming Group

Pharming Group Price Performance

The company has a market cap of $827.26 million, a PE ratio of -46.77 and a beta of -0.08. The business has a 50 day moving average of $9.14 and a 200 day moving average of $8.96. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.03. The firm had revenue of $79.09 million during the quarter, compared to analysts' expectations of $67.74 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. As a group, research analysts predict that Pharming Group will post -0.2 EPS for the current year.

About Pharming Group

(Get Free Report)

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Featured Articles

Should You Invest $1,000 in Pharming Group Right Now?

Before you consider Pharming Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.

While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines